Comparison of limited‐volume perioperative high‐dose‐rate brachytherapy and wide‐field external irradiation in resected head and neck cancer

Abstract

Complications and locoregional failure rates were similar to those reported in the reference standards despite a much smaller treatment volume.

Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application

“…Periopertive high dose rate brachytherapy alone after R0 resection has been associated with 9 year cancer-specific survival rate of 47.9%. 4 Martinez et al reported the 4 year local control rate and overall survival were 85.6 and 46.4%, respectively in head and neck cancers treated with reirradiation using PHDRB. 13,14 Treatment-related acute side-effects include bleeding, fistula, graft failure, delayed wound healing.…”

“…Gaztanaga et al have shown perioperative high dose rate brachytherapy to have equivalent treatment outcomes when compared to wide field radiotherapy with 5 year locoregional control rates from 60.9 to 79.4%. 4 …”

“…PHDRB can be used in head and neck cancers to primarily irradiate the tumor bed to a very high dose of radiation as a single modality or combined with external beam radiotherapy in both the primary treatment and for reirradiation of recurrent cancers. 4 We report here two cases highlighting the applications of perioperative brachytherapy in these clinical situations.…”

Cesium-131 Brachytherapy Seeds for the Treatment of Sinonasal Carcinosarcoma: A Case Report and Literature Review

“…Historically utilized most frequently in the treatment of gynecologic malignancies [21][22][23], BRT is now also an established therapeutic modality in the management of residual, recurrent and metastatic tumors of the head and neck region [15,16,[24][25][26][27][28][29]. EBRT of the sinonasal tract and nasopharynx may result in both acute and late toxicities due to secondary radiation exposure to the optic chiasm, optic nerve, orbit and brainstem, especially in the setting of prior skull base irradiation.…”

Braquiterapia adyuvante de alta tasa de dosis en el tratamiento de pacientes con carcinoma de cabeza y cuello: aplicabilidad de los datos dosimétricos

“…(2 fracciones al día -b.i.d.) en el caso de la braquiterapia HDR [138][139][140][141][142] , y de 60 Gy en el caso de la braquiterapia LDR administrados durante 4-5 días. 143,144 Las series de braquiterapia postoperatoria informan de tasas de control locorregional a 5 años entre el 74% y el 93%, 118,135,145 con los mejores resultados en aquellos tumores con estadio precoz tratados con braquiterapia postoperatoria exclusiva y los peores resultados en estadios avanzados tratados con la combinación de radioterapia externa y braquiterapia postoperatoria.…”